Factor V Leiden Mutation


Risk

  • Most common hereditary thrombophilia

  • Autosomal dominant inheritance pattern

  • Heterozygous form in 5% of white population in USA (up to 15% in Europe), 2% of Hispanic Americans, 1% in both African and Native Americans

  • Homozygosity in white population 1:5000

  • May account for 85–95% of pts with APC resistance

  • Relative risk of venous thrombosis sevenfold in heterozygous and 80-fold in homozygotes

Perioperative Risks

  • VTE: DVT most likely; lower risk of PE

  • Risk of arterial thrombosis unknown

Worry About

  • Hypercoagulability

  • DVT

  • Recurrent fetal loss (twofold to fivefold increased relative risk)

  • Conflicting data regarding association with placental abruption, severe preeclampsia, IUGR

  • Cerebral vein thrombosis

  • Renal transplant rejection

  • Risk of thrombosis increased by protein S deficiency, prothrombin 20210 gene mutation, hyperhomocysteinemia, OCP use, pregnancy, increasing age, immobilization, and obesity

Overview

  • Factor Va is a procoagulant that is inactivated by APC, with protein S as cofactor, causing less thrombin generation during the propagation phase.

  • FVL is resistant to inactivation by APC so thrombin generation is allowed to continue and subsequent clot formation.

  • FVL paradox describes the higher prevalence of FVL in pts with DVT compared with FVL pts with pulmonary embolism.

  • In CPB, FVL pts found to have less blood loss and need less blood transfusion during hospital stay.

  • Testing in FVL is the same as other causes of thrombophilia: Venous thrombosis and age <50 y; unusual sites of thrombosis (hepatic, mesenteric, cerebral); recurrent venous thrombosis; venous thrombosis with strong history of thrombotic disease, venous thrombosis in pregnant women taking oral contraceptives, relatives of pts who had venous thrombosis <50 y, MI in female smokers <50 y.

  • Screening test: Modified APC resistance functional assay (sensitivity and specificity for FVL close to 100%).

  • Confirmation test: DNA test. In liver transplant pts, DNA test positive, plasma FVL negative. In bone marrow transplant pts, DNA test negative, but plasma shows APC resistance.

You're Reading a Preview

Become a Clinical Tree membership for Full access and enjoy Unlimited articles

Become membership

If you are a member. Log in here